Vera Therapeutics reported net income of -$109.72M for the quarter ended Jun 2026. This income statement covers 26 quarters of results from Mar 2020 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Mar2020 | Jun2020 | Sep2020 | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 20.97M | 21.28M | 26.76M | 27.00M | 27.66M | 27.80M | 44.26M | 44.32M | 44.43M | 44.45M | 54.70M | 54.83M | 63.32M | 63.56M | 63.77M | 63.82M | 63.93M | 71.27M | 71.78M | 72.06M | ||||||
| Operating items | ||||||||||||||||||||||||||
| Research & DevelopmentR&D | 3.56M | 12.75M | 12.55M | 10.11M | 19.66M | 26.68M | 25.11M | 16.23M | 16.10M | 20.79M | 23.20M | 29.31M | 40.31M | 33.35M | 41.28M | 58.20M | 56.47M | 59.31M | 86.01M | 60.08M | ||||||
| Selling, General & AdministrativeSG&A | 3.69M | 3.83M | 4.47M | 4.95M | 5.59M | 6.91M | 6.15M | 5.74M | 5.66M | 6.24M | 7.91M | 8.03M | 9.49M | 15.57M | 15.92M | 21.95M | 27.46M | 34.90M | 39.12M | 52.41M | ||||||
| Restructuring CostsRestructuring | 0.03M | -0.12M | ||||||||||||||||||||||||
| Other Operating ExpensesOther Opex | ||||||||||||||||||||||||||
| Operating ExpensesOpex | 7.25M | 16.59M | 17.02M | 15.06M | 25.24M | 33.58M | 31.26M | 21.97M | 21.76M | 27.03M | 31.11M | 37.34M | 49.80M | 48.91M | 57.19M | 80.14M | 83.93M | 94.21M | 125.13M | 112.49M | ||||||
| Operating IncomeOp. Inc | -7.25M | -16.59M | -17.02M | -15.06M | -25.24M | -33.58M | -31.26M | -21.97M | -21.76M | -27.03M | -31.11M | -37.34M | -49.80M | -48.91M | -57.19M | -80.14M | -83.93M | -94.21M | -125.13M | -112.49M | ||||||
| EBIT | -7.25M | -16.59M | -17.02M | -15.06M | -25.24M | -33.58M | -31.26M | -21.97M | -21.76M | -27.03M | -31.11M | -37.34M | -49.80M | -48.91M | -57.19M | -80.14M | -83.93M | -94.21M | -125.13M | -112.49M | ||||||
| Non-operating items | ||||||||||||||||||||||||||
| Non Operating Interest Expenses | 0.02M | 0.12M | 0.13M | 0.15M | 0.60M | 0.87M | 0.91M | 0.94M | 1.06M | 1.91M | 1.91M | 1.94M | 1.87M | 1.79M | 1.87M | 1.96M | 1.90M | 1.82M | 1.85M | |||||||
| Non Operating Investment Income | -0.36M | -0.25M | -0.29M | -0.26M | -0.20M | -0.06M | -0.00M | -0.03M | -0.01M | -0.00M | -0.00M | -0.01M | ||||||||||||||
| Interest & Investment IncomeInt & Inv Inc | 0.01M | 0.01M | 0.03M | 0.26M | 0.57M | 0.89M | 1.62M | 2.24M | 2.16M | 1.96M | 4.19M | 5.10M | 4.76M | 6.66M | 6.91M | 6.32M | 5.74M | 5.52M | 6.36M | 5.35M | ||||||
| Non Operating IncomeNon Op. Inc. | -0.36M | -0.26M | -0.06M | 0.20M | 0.56M | 1.14M | 1.19M | 1.81M | 1.65M | 1.37M | 2.73M | 3.63M | 3.17M | 5.49M | 5.50M | 3.61M | 3.64M | 3.11M | 4.10M | 3.02M | ||||||
| Net income details | ||||||||||||||||||||||||||
| EBT | -7.25M | -16.60M | -17.11M | -14.92M | -24.82M | -33.29M | -30.51M | -20.64M | -20.54M | -26.12M | -28.83M | -34.15M | -46.98M | -44.12M | -52.08M | -75.69M | -80.16M | -90.59M | -120.60M | -108.99M | ||||||
| Profit After TaxPAT | -7.61M | -16.85M | -17.09M | -14.85M | -24.81M | -32.38M | -30.07M | -20.16M | -20.10M | -25.66M | -28.38M | -33.71M | -46.63M | -43.42M | -51.69M | -76.66M | -80.29M | -91.10M | -121.03M | -109.72M | ||||||
| Income from Non-Controlling InterestsInc. Minority | -7.61M | 48.37M | 17.10M | -14.99M | -24.81M | 56.66M | 29.85M | |||||||||||||||||||
| Income from Continuing OperationsIncome (Continuing) | -7.25M | -16.60M | -17.11M | -14.92M | -24.82M | -33.29M | -30.51M | -20.64M | -20.54M | -26.12M | -28.83M | -34.15M | -46.98M | -44.12M | -52.08M | -75.69M | -80.16M | -90.59M | -120.60M | -108.99M | ||||||
| Consolidated Net IncomeConsol Net Inc. | -7.25M | -16.60M | -17.11M | -14.92M | -24.82M | -33.29M | -30.51M | -20.64M | -20.54M | -26.12M | -28.83M | -34.15M | -46.98M | -44.12M | -52.08M | -75.69M | -80.16M | -90.59M | -120.60M | -108.99M | ||||||
| Income towards Parent CompanyParent Net Inc | -7.25M | -16.60M | -17.11M | -14.92M | -24.82M | -33.29M | -30.51M | -20.64M | -20.54M | -26.12M | -28.83M | -34.15M | -46.98M | -44.12M | -52.08M | -75.69M | -80.16M | -90.59M | -120.60M | -108.99M | ||||||
| Net Income towards Common StockholdersNet Income | -7.25M | -16.60M | -17.11M | -14.92M | -24.82M | -33.29M | -30.51M | -20.64M | -20.54M | -26.12M | -28.83M | -34.15M | -46.98M | -44.12M | -52.08M | -75.69M | -80.16M | -90.59M | -120.60M | -108.99M | ||||||
| Additional items | ||||||||||||||||||||||||||
| EPS (Basic) | -0.34 | -1.24 | -0.71 | -0.55 | -0.91 | -1.25 | -0.81 | -0.47 | -0.46 | -0.61 | -0.57 | -0.62 | -0.86 | -0.80 | -0.82 | -1.19 | -1.26 | -1.41 | -1.69 | -1.52 | ||||||
| EPS (Diluted) | -0.34 | -1.24 | -0.71 | -0.55 | -0.91 | -1.25 | -0.81 | -0.47 | -0.46 | -0.61 | -0.57 | -0.62 | -0.86 | -0.80 | -0.82 | -1.19 | -1.26 | -1.41 | -1.69 | -1.52 | ||||||
| Shares Outstanding | 21.27M | 13.44M | 24.23M | 27.08M | 27.22M | 26.57M | 37.67M | 44.27M | 44.36M | 42.71M | 50.97M | 54.73M | 54.90M | 55.33M | 63.67M | 63.79M | 63.85M | 64.23M | 71.48M | 71.84M | ||||||
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 21.27M | 13.44M | 24.23M | 27.08M | 27.22M | 26.57M | 37.67M | 44.27M | 44.36M | 42.71M | 50.97M | 54.73M | 54.90M | 55.33M | 63.67M | 63.79M | 63.85M | 64.23M | 71.48M | 71.84M | ||||||
| EBITDA | -7.25M | -16.59M | -17.02M | -15.06M | -25.24M | -33.58M | -31.26M | -21.97M | -21.76M | -27.03M | -31.11M | -37.34M | -49.80M | -48.91M | -57.19M | -80.14M | -83.93M | -94.21M | -125.13M | -112.49M | ||||||
| Interest ExpensesInt Expense | 0.02M | 0.12M | 0.13M | 0.15M | 0.60M | 0.87M | 0.91M | 0.94M | 1.06M | 1.91M | 1.91M | 1.94M | 1.87M | 1.79M | 1.87M | 1.96M | 1.90M | 1.82M | 1.85M |